"L’Istituto Clinico Sant’Ambrogio si pone come eccellenza nazionale in particolare in due aree: Cardiovascolare e Diagnosi e Cura dell’Obesità. Quanto alla prima, il Centro Cardiotoracico e la Cardiologia Interventistica rappresentano una realtà d’eccellenza negli interventi di cardiochirurgia mininvasiva e nella sostituzione della valvola aortica per via percutanea. Per la seconda, la Struttura è sede dal 2010 dell’Istituto Nazionale per la Chirurgia dell’Obesità (INCO), riferimento nazionale per la diagnosi e cura del trattamento multidisciplinare dell’obesità. Grazie a INCO, si effettuano trattamenti dietologici, psico-comportamentali e interventi chirurgici con le più innovative tecniche videolaparoscopiche e mininvasive."

During the past decade, Istituto Clinico S.Ambrogio conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto Clinico S.Ambrogio" #1 sponsor was "Istituto Clinico Sant'Ambrogio" with 4 trials, followed by "Abbott Medical Devices" with 2 trials sponsored, "European Institute of Oncology" with 2 trials sponsored, "Medtronic Bakken Research Center" with 2 trials sponsored and "Luigi Sacco University Hospital" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Clinico S.Ambrogio" #1 collaborator was "Centro Cardiologico Monzino" with 2 trials as a collaborator, "Abbott Medical Devices" with 1 trials as a collaborator, "Azienda Ospedaliera Niguarda Cà Granda" with 1 trials as a collaborator and "Istituto Clinico Humanitas" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Clinico S.Ambrogio" are "Coronary Artery Disease" (5 trials), "Coronary Arteriosclerosis" (2 trials), "Coronary Artery Restenosis" (2 trials), "Coronary Artery Stenosis" (2 trials) and "Myocardial Ischemia" (2 trials). Many other conditions were trialed in "Istituto Clinico S.Ambrogio" in a lesser frequency.

Most popular intervention types in "Istituto Clinico S.Ambrogio" are "Device" (8 trials), "Drug" (3 trials), "Procedure" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "DES+DCB" (2 trials), "XIENCE V®/ XIENCE PRIME™" (2 trials), "ABSORB implantation" (1 trials), "ANTHEM™ CR Total Knee System" (1 trials) and "ANTHEM™ PS Total Knee System implant" (1 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Clinico S.Ambrogio" are 11 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Istituto Clinico S.Ambrogio". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 4 completed trials in Istituto Clinico S.Ambrogio, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Clinico S.Ambrogio, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 2 trials that are defined as “Not Applicable".